Management of Indirect Neonatal Hyperbilirubinemia

Patient population: This guideline applies to the management of indirect hyperbilirubinemia in neonates less than 8 days of life and 35 weeks gestation or more. This guideline does not include the management of neonatal direct hyperbilirubinemia or hyperbilirubinemia in patients greater than 8 days of age. This guideline excludes premature neonates born prior to 35 weeks gestation.

Objectives: To create an evidence-based standard for the management of neonates with indirect hyperbilirubinemia across all care settings (newborn nursery, intensive care units, general inpatient service, home care, primary care, and emergency department) that provides appropriate care to patients, reduces unnecessary diagnostic tests and interventions, and improves patient outcomes.

Key points:

Prevention. Feed newborns, starting at birth, at least 8 times per day. Feedications should be based on feeding cues with attempts at least every 3 hours.

Continue breastfeeding even if feeding difficulties arise. In certain circumstances, expressed breast milk or formula supplementation may be warranted. Discourage discontinuation of breastfeeding, even for diagnostic purposes in the setting of suspected breast-milk jaundice.

Feeding supplementation is not indicated for sleepy neonates during first 24-48 hours, unless signs of dehydration, or weight loss more than the 95th percentile per the newborn weight tool (NEWT).

Feeding recommendations are not relevant if a patient is critically ill and enteral feeds are being withheld.

Diagnosis. The approach to diagnosing hyperbilirubinemia will differ depending on whether it is detected via screening during the birth hospitalization (see Figure 1) or later in follow-up (see Figure 2).

History. Assess all newborns for risk factors for developing hyperbilirubinemia. (Table 1)

Bilirubin Measurement. A total bilirubin (TSB or TcB) level should be measured on all newborns prior to discharge. [I-C]

Choose appropriate test for bilirubin levels (Table 5)

If TSB is indicated, the first level should be fractionated to rule out direct hyperbilirubinemia. Subsequent measurements can be total bilirubin alone.

The first measurement should be obtained at 16-24 hours of life. [I-C]

Discharge prior to 16 hours of life is strongly discouraged. If extenuating circumstances result in the discharge of a neonate prior to 16 hours of life, appropriate follow-up for evaluation of hyperbilirubinemia should be arranged.

Total bilirubin levels should be plotted on the hour-specific nomogram to direct follow up (Figures 4 & 5). If POC bilirubin is obtained in the outpatient setting, consider that serum measurements can be 10% higher when interpreting the results.

Further investigation into underlying etiology. Investigation into rarer causes of hyperbilirubinemia is recommended in certain circumstances (Table 4).

Risk Stratification. Use risk stratification (lower, medium, or higher risk (Table 3) to determine phototherapy and exchange-transfusion thresholds. To risk stratify, combine gestational age (GA) with presence of neurotoxicity risk factors (Table 1). [I-D]

Treatment. For overview, see Figure 3.

Decision to admit to the hospital and treat should be based on TSB. [I-D]

Intensive phototherapy can be expected to decrease bilirubin levels by 30-40% in 24 hours, with most being in the first 4-6 hours. Intensive phototherapy should be initiated in the following circumstances:

- when total bilirubin is at or above the phototherapy treatment threshold based on hour-specific nomograms (Figure 4)
- when TSB rate of rise >0.2 mg/dL/hour and TSB is predicted to cross treatment threshold prior to next evaluation [I-D]

There is lack of evidence to support the routine use of home phototherapy when the bilirubin level is at, near, or above the treatment threshold. However, home phototherapy can be considered when bilirubin is 0-2 mg/dL below the treatment threshold at discharge from the birth hospitalization or in the outpatient setting in the following circumstances:

* Strength of recommendation:
  1 = generally should be performed; II = may be reasonable to perform; III = generally should not be performed.

Level of evidence supporting a diagnostic method or an intervention:

A = randomized controlled trials; B = controlled trials, no randomization; C = observational trials; D = opinion of expert panel, E = opinion of expert panel.
Neonates who feed well, appear well, and have close follow up arranged.
Neonates with no neurotoxicity risk factors (low risk or medium risk based on gestational age alone) [III-C]
Neonates without prior history of intensive phototherapy treatment

When bilirubin values are at or near exchange transfusion values:
  - Maximize surface area exposed to phototherapy by removing unnecessary clothing (minimal/no diaper)
  - Use highly reflective materials to surround the neonate to increase surface area exposed and irradiance
  - Use multiple light sources (measure irradiance at various sites)
  - Consider adjunctive therapies, including Intravenous immunoglobulin (IVIG) and IV hydration
  - Notably, turning baby from prone to supine in an alternating fashion has not been shown to be efficacious

For most neonates, routine IV supplementation is not warranted. However, for neonates with severe hyperbilirubinemia, IV fluid administration may be useful and is recommended.

Use of IVIG may be useful in Rh or ABO disease.
  - Use should be restricted to select neonates in the NICU with high bilirubin values or rapid rate of rise (at high risk for exchange transfusion).
  - Neonates should be monitored closely.
  - Dose 0.5g/kg over 2 hours, repeat as clinically indicated.

An exchange transfusion should be considered when a serum bilirubin value surpasses the applicable AAP recommended threshold value (Figure 5).

**Monitoring.** Following the initiation of phototherapy, only serum bilirubin (TSB) levels are recommended.
Stop phototherapy once serum bilirubin has fallen to a level at least 3 mg/dL below the phototherapy threshold.
Rebound levels at 6 hours are not predictive of subsequent repeat phototherapy.
If treated prior to initial hospitalization discharge (post-delivery), consider repeat TSB 24 hours after discontinuation of phototherapy. This can be done as an outpatient.
If preterm, DAT+, or treated after readmission and serum bilirubin is greater than 14, recheck TSB 12-24 hours after discontinuation of phototherapy. This can be done as an outpatient. (If bilirubin ≤14, routine repeat TSB is not indicated in all neonates.)
When treating with exchange transfusion, recheck bilirubin q 4-6 hours, depending on the rate of decline.
A neonate being treated with home phototherapy (fiber optic blanket, Bili Blanket) should have a TSB checked:
  - every 24-48 hours if the neonate is low risk
  - every 24 hours if the neonate is medium risk and has no neurotoxicity risk factors
Discharge should not be delayed to obtain a rebound bilirubin level. Rebound levels can be checked as an outpatient when indicated.

**Follow-up.** Timing and frequency of follow up after birth hospitalization should be influenced by risk of development of severe hyperbilirubinemia. This can be determined by risk factors for development of severe hyperbilirubinemia (Table 2) as well as plotting TcB or TSB on the Bhutani nomogram (Appendix 1)
  - For those at higher risk, follow up should occur 1 day following birth hospitalization discharge
After hospital discharge from phototherapy, PCP follow-up should be arranged within 24 hours, or 48 hours when no serum bilirubin recheck is required (i.e. discharge bilirubin <14).

**Phototherapy Techniques.** Fiberoptic Phototherapy Blanket: The fiber optic blanket should be applied next to the neonate’s skin.
  - The neonate may wear a diaper. The parents should swaddle the neonate with the fiber optic blanket next to the skin to avoid hypothermia. Feeding can continue with the blanket next to the neonate’s skin. If necessary, to optimize feeding, the neonate may be removed from the blanket for up to 30 minutes every 2-3 hours.

Inpatient Phototherapy:
  - Babies receiving inpatient phototherapy should receive “intensive” phototherapy. [I-C]
  - For the majority of term neonates, phototherapy using a single overhead LED light source will provide intensive phototherapy and will be sufficient.
Phototherapy using a single overhead LED light source and fiberoptic blanket may be indicated when the serum bilirubin value is:
  - rising more than 0.5mg/dl/hour
  - within 3mg/dl below the exchange transfusion threshold
  - fails to respond to initial phototherapy
Use of 2 angled overhead lights, a fiberoptic blanket, and white sheets as a reflective surface may be indicated when bilirubin is at or above the exchange transfusion threshold. This is done in the NICU.
  - body surface area exposed and continuity of therapy (i.e. minimizing interruptions) will influence efficacy.
  - irradiance should be measured regularly.
  - there is a lack of evidence to support the use of fiberoptic blanket alone.
  - when neonates are not considered high risk for exchange transfusion, phototherapy can be temporarily halted to allow for bonding and breastfeeding.
Definitions

**Direct or conjugated hyperbilirubinemia**: conjugated bilirubin of 1 mg/dL or more when total bilirubin is less than 5 mg/dL or 20% of total bilirubin when total bilirubin is over 5 mg/dL.¹

**Home phototherapy** (Fiberoptic phototherapy Blanket): phototherapy provided via a fiberoptic blanket in the home setting

**Infant jaundice studies** (IJS): A set of tests including neonatal blood typing for ABO and Rh as well as direct antiglobulin test (DAT), typically performed using cord blood. (Note: at UMHS, results regarding maternal ABO status are listed in “comment” area.)

**Inpatient phototherapy**: All inpatient phototherapy is intensive. The method of delivery (number of light sources) is dependent on the clinical state of the infant.²

**Intensive phototherapy**: A light source that provides between 30 microwatts/cm² per nm and 65 microwatts/cm² per nm and delivered to as much of the infant’s surface area as possible.

**Prolonged jaundice**: > 14 days for term; > 21 days for preterm

**Total serum bilirubin** (TSB): A blood test to measure bilirubin levels, both direct bilirubin and indirect bilirubin

**Transcutaneous bilirubin** (TcB): A non-invasive measure to estimate serum bilirubin levels

Abbreviations

**AAP**: American Academy of Pediatrics

**ABE**: Acute bilirubin encephalopathy

**AOD**: Admitting officer of the day (Hospitalist taking outside hospital transfer and direct admission calls)

**Ca**: Calcium

**CBC**: Complete blood count

**CES**: Children Emergency Services

**DAT**: Direct antiglobulin test

**G6PD**: Glucose-6-phosphate dehydrogenase

**HOL**: Hours of life

**IJS**: Infant (neonate) jaundice studies

**IVIG**: Intravenous immunoglobulin

**MVN**: Michigan Visiting Nursing

**Na**: Sodium

**NEWT**: Newborn weight tool

**NICU**: Neonatal intensive care unit

**PLT**: Platelet

**POC**: Point of Care

**TcB**: Transcutaneous bilirubin

**TSB**: Total serum bilirubin

**Tx**: Treatment

**UMHS**: University of Michigan Health System
Figure 1. Birth Hospitalization

Determine neurotoxicity risk category for phototherapy threshold (Table 1 and 3)

Screen TcB from sternum @16-24 HOL

Plot

No

TcB +3 cross threshold?

Yes

Send TSB + IJS* (1st TSB should be fractionated)

TSB within 2?

>2 below

Within 2

≥ Tx threshold

No

Increasing clinical signs of jaundice

Yes

Re-check screening TcB at 36 HOL (or sooner if clinically indicated), then q24hrs if patient at higher risk for developing severe hyperbili (Table 1)

clinically monitor


clinically monitor

Resend TSB

Intensive phototherapy

Continue to clinically monitor
Figure 2. Outpatient Hyperbilirubinemia

**Figure 2. Outpatient Hyperbilirubinemia**

- Determine neurotoxicity risk category for phototherapy threshold (Table 1 and 3)
- Visible jaundice on exam
- Obtain TSB vs TcB
- Plot according to hour-specific phototherapy threshold (Figure 5).
  - Bili at Tx threshold?
    - Bili >1=2 below Tx threshold
      - Continue to clinically monitor
    - Bili within 2 of Tx threshold
      - Obtain IJS** Continue to clinically monitor
  - Bili ≥ Tx threshold, or rate of rise >0.2mg/dL/hr
    - Obtain IJS**
    - Bili at or above exchange level
      - No
      - Yes
        - Recheck TcB in 24hr†
        - Arrange for direct admission to Pediatric Hospitalist Service (Gen care)***
        - Arrange direct admission to Neonatology Service (NICU)****

* TcB acceptable when:
  - available
  - no prior hx of phototherapy
  - Confirm all TcB results within 3 mg/dL of Tx threshold with TSB

** Send IJS when sending serum bilirubin if not previously done. Adjust risk category for phototherapy threshold if DAT+. This should be done prior to decision on Tx

*** At UMHS, page 2288 for UM providers; call AOD/MLine 800-962-3555 for outside providers

**** At UMHS, call NICU 763-4111, ask for fellow

IJS = infant jaundice studies; HOL = hours of life; TcB = Transcutaneous Bili; TSB = Trans Serum Bilirubin; Tx = Treatment
† Although there is no evidence to support this, home phototherapy can be considered for infants without neurotoxicity risk factors who are within 2 of treatment threshold; DAT+ = Direct antiglobulin test (positive)
**Figure 3. Hyperbilirubinemia Treatment**

<table>
<thead>
<tr>
<th><strong>Bilirubin level</strong></th>
<th><strong>Phototherapy technique</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>At or above phototherapy threshold, or rate of rise &gt; 0.2 mg/dL/hr</td>
<td>Single overhead LED light</td>
</tr>
<tr>
<td>Within 3 mg/dL of exchange level, rate of rise &gt; 0.5 mg/dL/hr, or failure to improve with single overhead light</td>
<td>Single overhead LED light</td>
</tr>
<tr>
<td>At or above exchange transfusion level</td>
<td>Admit to NICU</td>
</tr>
<tr>
<td></td>
<td>2 angled overhead LED lights</td>
</tr>
<tr>
<td></td>
<td>Fiberoptic phototherapy blanket</td>
</tr>
<tr>
<td></td>
<td>White sheets</td>
</tr>
</tbody>
</table>

*Continue to encourage breastfeeding. Consider lactation consultant. If clinically dehydrated, consider oral rehydration versus IVFs.

**Tx** = treatment; **TSB** = Total Serum Bilirubin; **IVF** – IV Fluids
Use total bilirubin. Do not subtract direct reacting or conjugated bilirubin.

Adapted with permission from The American Journal of Pediatrics, Vol. 114, p. 20, Copyright © 2004 by the AAP.
Table 1. Neurotoxicity Risk Factors*

<table>
<thead>
<tr>
<th>Isoimmune hemolytic disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>G6PD deficiency</td>
</tr>
<tr>
<td>Asphyxia</td>
</tr>
<tr>
<td>Significant lethargy</td>
</tr>
<tr>
<td>Temperature instability</td>
</tr>
<tr>
<td>Sepsis**</td>
</tr>
<tr>
<td>Acidosis</td>
</tr>
<tr>
<td>Albumin &lt;3.0g/dL (if measured. Note: It is not necessary to draw an albumin for a well-appearing neonate unless otherwise indicated.)</td>
</tr>
</tbody>
</table>

*Only neurotoxicity risk factors alter the baby’s risk level for determining phototherapy threshold.
**Neonates being treated with antibiotics for suspected sepsis should be considered to have a neurotoxicity risk factor. This risk factor may be discounted when sepsis is no longer suspected and antibiotics are discontinued.

Table 2. Risk Factors for the Development of Severe Hyperbilirubinemia

<table>
<thead>
<tr>
<th>Major risk factors:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predischarge bilirubin level in the high-risk zone on Bhutani nomogram (Appendix 1)</td>
</tr>
<tr>
<td>Visible jaundice in the first 24 hours of life</td>
</tr>
<tr>
<td>Blood group incompatibility with positive direct antiglobulin test* (A neonate should NOT be presumed to have ABO incompatible hemolytic disease solely on the basis of maternal blood type O.)</td>
</tr>
<tr>
<td>Known hemolytic disease (e.g. G6PD deficiency) *</td>
</tr>
<tr>
<td>Gestational age &lt; 37 weeks</td>
</tr>
<tr>
<td>Previous sibling received phototherapy</td>
</tr>
<tr>
<td>Cephalohematoma or significant bruising</td>
</tr>
<tr>
<td>Exclusive breastfeeding</td>
</tr>
<tr>
<td>East Asian race</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Minor risk factors:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predischarge bilirubin level in the high intermediate-risk zone</td>
</tr>
<tr>
<td>Gestational age 37-38 weeks</td>
</tr>
<tr>
<td>Visible jaundice before discharge</td>
</tr>
<tr>
<td>Macrosomic neonate of a diabetic mother</td>
</tr>
<tr>
<td>Maternal age ≥ 25 years</td>
</tr>
<tr>
<td>Male gender</td>
</tr>
</tbody>
</table>

*Also related to neurotoxicity risk factor, see neurotoxicity risk factors. (Certain risk factors increase likelihood of severe hyperbilirubinemia, others increase neurotoxicity risks; some risk factors increase both.)
Table 3. Risk Levels for Determining Phototherapy Threshold

<table>
<thead>
<tr>
<th>Level</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower risk</td>
<td>≥ 38 weeks without neurotoxicity risk factors</td>
</tr>
<tr>
<td>Medium risk</td>
<td>≥ 38 weeks with neurotoxicity risk factors OR 35-37 6/7 weeks without</td>
</tr>
<tr>
<td></td>
<td>neurotoxicity risk factors</td>
</tr>
<tr>
<td>Higher risk</td>
<td>35-37 6/7 weeks with neurotoxicity risk factors</td>
</tr>
</tbody>
</table>

Note: Risk level should not change when there is ABO incompatibility without hemolysis. However, it would be prudent to monitor the baby more closely since DAT can be falsely negative.

Table 4. Circumstances Meriting Consideration of Rare Causes for Hyperbilirubinemia

- Severe hyperbilirubinemia ≥ 25mg/dL
- Poor response to phototherapy
- Recurrent admissions for hyperbilirubinemia
- Direct hyperbilirubinemia
- Prolonged jaundice (> 14d for term; > 21 days for preterm)
- Family history of Glucose-6-phosphate dehydrogenase (G6PD) deficiency or ethnicity suggestive of G6PD deficiency
- Family history of non-immune hemolytic diseases, such as hereditary spherocytosis

Table 5. Indications for Bilirubin Testing Modalities and Infant Jaundice Studies

<table>
<thead>
<tr>
<th>Trans-cutaneous Bilirubin (TcB)</th>
<th>Total Serum Bilirubin(TSB)</th>
<th>Infant Jaundice Study (IJS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reasonable estimate for serum bilirubin levels when the level is &lt; 13mg/dL.</td>
<td>The initial serum bilirubin should be fractionated to evaluate for direct hyperbilirubinemia. Subsequent draws can be total bilirubin alone. Obtain when: Considering phototherapy or other treatment [I-D] Management would change at TcB + 3 TcB is &gt; 15 [I-C]³ There is visible jaundice in the first 24 hours [II-D]⁴</td>
<td>Should be obtained when: Considering phototherapy or other treatment. [I-D] Mother has not had prenatal testing for blood type and antibody screen. [I-D] Mother has potentially significant antibodies [I-D] Bilirubin is less than treatment threshold, but rapidly rising (rate of rise &gt; 0.2mg/dL/hr). [II-D]</td>
</tr>
<tr>
<td>In the outpatient setting (clinic or visiting nurses), TcB may be used to assess neonatal hyperbilirubinemia.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Contraindications:
- Do not use TcB if phototherapy has been initiated

Should not be routinely obtained for:
- All mothers with blood type O. Use only when indicated (see above).
- All Rh+ neonates of Rh- mothers who were treated with Rho(D) immune globulin (e.g. rophylac, RhoGAM™). DAT has a low positive predictive value for later hyperbilirubinemia and there is a risk of false positive after RhoGAM. Use only when indicated (see above).

DAT = direct antiglobulin test

---

9 UMHS Neonatal Hyperbilirubinemia Guideline October 2017
Clinical Background

Background and Epidemiology

Between 0.4 and 6.2% of healthy > 35 week newborns receive phototherapy for indirect hyperbilirubinemia, and severe hyperbilirubinemia occurs in approximately 7-45 neonates per 100,000 live births. The definition of severe hyperbilirubinemia varies, but typically refers to bilirubin levels between 25 mg/dL to 30 mg/dL.

There are several factors that increase a newborn’s risk for development of severe hyperbilirubinemia. A systematic review done in 2010 concluded factors associated with severe hyperbilirubinemia were age < 38 weeks, jaundice within 24 hours of life and intention to breastfeed exclusively. In this review, four out of five studies evaluated family history of jaundice as a risk factor and four found it to be statistically significant. Large cohort studies since then confirm some of these findings. Male gender and non-Caucasian race increase the probability of high total serum bilirubin (TSB) as does evidence of cephalohematoma. “Dehydration/starvation,” usually measured as a percentage of weight loss since birth, is associated with hyperbilirubinemia. “Exclusive breastfeeding” is often found as a risk factor.

Complications

Unbound and unconjugated (free) bilirubin is neurotoxic. Brain damage caused by hyperbilirubinemia requires that a quantity of (free) bilirubin to chemically interact with neurons. The concentration of bilirubin sufficient to cause neuronal cell injury is speculative. The concentration of free bilirubin in the central nervous system and the underlying “susceptibility” of neurons (independent of bilirubin concentration) are key determinants of injury, neither of which is easily measured. The amount of free bilirubin is dependent upon the total serum bilirubin value, the albumin (principle “binder” of bilirubin) concentration, and the chemical kinetics governing the binding of the two. This can be affected by gestational age, concomitant illness and any other compounds competing for bilirubin binding sites. A separate set of kinetics governs the transfer of bilirubin from blood into (and out of) the central nervous system (CNS). These kinetics can be affected by underlying illness.

At present there is no practical way to measure free CNS bilirubin; hence TSB is used as a surrogate. The susceptibility of the CNS is regional in nature; neurons in the basal ganglia and cerebellum appear most susceptible. It is reasonable to assume that underlying cellular “stress” can render certain neurons more vulnerable (e.g. hypoxia, inflammation).

The bottom line is that at any given time for any given baby there exists a serum bilirubin value that can cause injury, but what that actual value is will always be speculative. Clinical studies in this area focus on values of TSB that are associated with acute bilirubin encephalopathy (ABE) and chronic bilirubin encephalopathy (CBE), and recognizable clinical conditions that are associated with ABE and CBE. These studies seek to define probability estimates (or action threshold probabilities) that trigger clinician behaviors (e.g. identify risk, identify TSB threshold for phototherapy, and identify TSB threshold for exchange transfusion). In the early phase of ABE, neonates are described as having poor feeding, lethargy, high-pitched cry, increased tone, opisthotonos, or seizures. Later acute encephalopathy is characterized by retrocoliosis-opisthotonos, shrill cry, no feeding, apnea, fever, deep stupor to coma, sometimes seizures, and death. Sequelae of CBE include: motor delay, sensorineural hearing loss, upward gaze palsy, dental dysplasia, athetoid cerebral palsy, or mental retardation.

The incidence of severe hyperbilirubinemia with subsequent encephalopathy is fairly consistent throughout large epidemiologic studies, at approximately 0.5 to 1.0 cases per 100,000 live births (Canada 2.5/100,000). Most provide no statistical data; the absolute number in each with CBE is very small. A large percentage of neonates with chronic bilirubin encephalopathy (CBE) had additional risk factors, among the most common being hemolysis (isoimmunization, G6PD deficiency, spherocytosis), late prematurity, and infection. Some had multiple risk factors.

The use of “high risk” categorization is justified in that risk factors are used in conjunction with TSB values to determine overall risk of extreme hyperbilirubinemia, a prerequisite for CBE.

Prevention

Exclusive breastfeeding is recommended during first 6 months of life, as all-cause mortality is less in exclusive breast fed neonates. Exclusive breastfeeding is strongly associated with an increased risk of hyperbilirubinemia, however, the hyperbilirubinemia appears to be primarily the result of less effective breastfeeding. To ensure successful breast feeding, lactation support should be initiated in the hospital if any difficulty is suspected, and continued in the physician’s office and at home (e.g. at UMHS, patient educational materials such as Feeding the Baby Born Before 38 Weeks).

The American Academy of Pediatrics recommends promoting breastfeeding for all term neonates at least eight to 12 times per day during first several days of life to reduce likelihood of dehydration. Breastfeeding women whose neonates are jaundiced are at increased risk of early cessation of breastfeeding. Unless the level is approaching threshold for exchange transfusion, mothers should be encouraged to breastfeed, and given lactation support if experiencing difficulty in breastfeeding. If phototherapy during breast feeding is possible, it can be encouraged.

A lactation support team should be consulted when inadequate breastfeeding is suspected. Supplementation with formula may be considered if the neonate’s intake is
inadequate, weight loss is more than the 95th percentile per NEWT, the neonate appears dehydrated, or the jaundice is severe. Signs of adequate intake in breast-fed neonates include four to six thoroughly wet diapers per day, three to four stools per day by the fourth day of life, and a transition to seedy, mustard-colored stools by the third or fourth day of life.4

It is recommend that feeding of all newborns occurs at least eight times per day starting immediately following birth.19 We recommended that babies be kept skin to skin and feed based on feeding cues with attempts at least every three hours. Feeding supplementation is not indicated for sleepy neonates during first 24-48 hours, unless there are signs of dehydration or weight loss is more than the 95th percentile per NEWT.4 UMHS guidelines for supplementation for difficult to latch term neonate during first 4 days are shown below. This recommendation is based on average intake of colostrum by healthy breast fed neonates.20,21

<table>
<thead>
<tr>
<th>Time after birth</th>
<th>Amount to feed</th>
</tr>
</thead>
<tbody>
<tr>
<td>12-24 hours</td>
<td>5-10ml q2-3hrs</td>
</tr>
<tr>
<td>24-48 hours</td>
<td>10-30ml q2-3hrs</td>
</tr>
<tr>
<td>48-72 hours</td>
<td>15-30ml q2-3hrs</td>
</tr>
<tr>
<td>72-96 hours</td>
<td>30+ ml 8 times/day or more</td>
</tr>
</tbody>
</table>

Diagnostic procedures and considerations. A total bilirubin should be measured on all babies prior to discharge from the birth hospitalization. [I-C]22 Compared with selective testing, universal screening reduces total blood draws and phototherapy rates.23,24 While several clinical risk scores have been developed, none are as predictive of subsequent hyperbilirubinemia as a predischarge bilirubin level.25

Transcutaneous (TcB) levels should be used for screening. Transcutaneous levels are reasonable estimates for serum levels, [I-C]2 and can be done rapidly and without a blood draw. TcB should be obtained from the sternum in neonates to avoid false negative that may be associated with the neonates face being in the sun.

The predischarge TcB should be obtained between 16 and 24 hours of life. [I-C] (UMHS guideline regarding measurement of transcutaneous bilirubin.)

Predischarge screening bilirubin levels should be used to guide follow-up. The hour-specific Bhutani nomogram can be used to predict the likelihood of subsequent significant hyperbilirubinemia found in Appendix 1. [I-C] 22,26 Significant hyperbilirubinemia in this case is defined as greater than the 95th percentile on the nomogram, and does not necessarily correlate with a need for phototherapy or exchange transfusion, length of stay, or neurologic outcomes. The hour-specific nomogram has been validated for patients with ABO incompatibility and positive direct antiglobulin test, and may be used in this population.27

A serum bilirubin (TSB) is recommended in the circumstances outlined in Table 5.

Infant jaundice studies [IJS; Neonatal blood typing for ABO and Rh as well as direct antiglobulin test (DAT)] should be obtained in circumstances outlined in Table 5.

Infant jaundice studies should not be measured routinely in all babies born to mothers with blood type O. [III-C]11,28 Only 15% of neonates with ABO-incompatibility and a positive DAT will develop significant hyperbilirubinemia.11 Those that do have ABO-hemolytic disease develop clinically significant jaundice in the first 12-24 hours of life and will be recognized with routine screening.

TcB can be used in the outpatient setting, including in the clinic or by a visiting nurse, to assess jaundice. This will reduce lab draws by 20-50%. [II-C]29

Cord blood DAT should not routinely be tested for in a Rh+ neonate of a Rh- mother who was treated with RhoGAM. It has a low positive predictive value for later hyperbilirubinemia and there is a risk of false positive after RhoGAM. [III-C]30 If phototherapy is being considered, DAT should be evaluated via cord blood or blood draw. [I-C]4

We recommend against withholding breast milk for diagnostic purposes in the setting of suspected breast milk jaundice. Significant hyperbilirubinemia is primarily the result of less effective breastfeeding,15 rather than breastfeeding itself. Neonates with jaundice were twice as likely as those without jaundice to have mothers who had stopped breastfeeding by one month (number needed to harm = 4).17

Common causes for hyperbilirubinemia include blood type incompatibility, G6PD deficiency, and infection. No cause was found in 1/3 of cases of neonates discharged healthy and returning with kernicterus in a sample of 125 neonates of 35 weeks or greater gestational age.9,31 There are several instances when further investigation into underlying etiologies for hyperbilirubinemia are suggested (Table 4).

Suggested testing when investigating underlying etiologies for indirect hyperbilirubinemia include DAT if not previously done, G6PD, hemoglobin/hematocrit, reticulocyte count, peripheral smear (RBC indices), complete blood count with differential, blood cultures and urine cultures.

Risk stratification. Neonates should be assigned a neurotoxicity risk level—lower, medium, or higher (Table 3) —based on gestational age and presence of neurotoxicity risk factors. [I-D]4 (Figure 4 & 5, Table 1)

The risk level is used to determine the hour-specific threshold for phototherapy and exchange transfusion.

Do not presume the presence of hemolytic disease, and thus a neurotoxicity risk factor, solely on the basis of maternal blood type O. [III-C]11,28,32

Neonates being treated with antibiotics for suspected sepsis should be considered to have a neurotoxicity risk factor. [I-
In the presence of hyperbilirubinemia, sepsis increases the risk of bilirubin encephalopathy 20-fold or greater. This risk factor may be discounted when blood cultures return negative and antibiotics are discontinued.

**Level of Care**

Treatment can range from hospital care to home care. Considerations of the various levels of care are listed below.

**Transfer from the newborn nursery to the floor.** Considerations for transferring newborns with hyperbilirubinemia to the floor will depend on local policies and resource availability. For UMHS, there are UMHS guidelines (Appendix 2) that address when to move a newborn with hyperbilirubinemia from the newborn nursery to the general pediatrics floor.

**Triage for visiting nursing.** If a visiting nurse (RN) has a transcutaneous bilimeter available, and measurement is within 3 mg/dL of treatment threshold, the visiting RN should communicate with the primary care provider (PCP), or discharging physician if PCP relationship has not been established, and unable to begin relationship sooner (i.e., same day appointment) for follow-up serum bilirubin. The PCP should facilitate further evaluation and laboratory follow-up. (UMHS MVN TcB policy UMHS internal use only.)

When there is visible jaundice or other concerns such as poor feeding, lethargy, or excessive weight loss, and no transcutaneous bilimeter is available, refer to the PCP (or discharging physician if the PCP relationship has not been established).

**Outpatient assessment** (Figure 2). All neonates discharged prior to 72 hours of life should be seen by a medical provider within 3 days (preferably within 48 hours) to assess for hyperbilirubinemia. Those at higher risk of severe hyperbilirubinemia should be evaluated sooner (preferably the day following birth hospitalization discharge). Risk factors for severe hyperbilirubinemia are listed in Table 2. Bilirubin level can also be plotted on the Bhutani nomogram (Appendix 1) to determine risk of development of severe hyperbilirubinemia and help guide follow up. Outpatient follow up assessments should include the neonates’ weight, percent change from birth weight (BW), adequacy of feeding, pattern of voiding and stooling, and presence of jaundice. Exclusively breast fed newborns are higher risk for hyperbilirubinemia and dehydration; close follow up until 7-9 days is recommended as 90% of severe hyperbilirubinemia can occur by day nine. Bilirubin measurement is determined by risk factors for hyperbilirubinemia, neurotoxicity risk factors, and clinical judgment.

The UMHS guideline outlining assessment of bilirubin can be found in Appendix 2. If a baby requires assessment of bilirubin during hours when clinics are closed, the on-call physician may order bilirubin levels and follow up the result. If labs are also closed, these patients can be directed to Children’s Emergency Services (CES) for a phlebotomy lab draw to be followed up by the outpatient, ordering provider. (At UMHS, guidance available at UMHS Department of Pathology - After Hours Phlebotomy Services) If there is concern about the clinical appearance of the patient and the neonate requires assessment by a provider, they may be referred to CES for evaluation. Whenever sending a patient to CES, it is the provider’s responsibility to provide handoff to the ED physicians.

If repeat bilirubin is needed following initial hospital discharge and before an appointment with the outpatient provider, it is the responsibility of the discharging physician to order and follow up on the bilirubin level.

If TSB is more than 2 mg/dL below the phototherapy threshold, there is no need to repeat TSB unless worsening jaundice, feeding difficulties, dehydration, sepsis, or other concerns.

If TSB is 0-2 mg/dL below phototherapy threshold, the provider should repeat TSB within 24 hours unless bilirubin level is decreasing compared to previous measurement. Consider ordering DAT from cord blood to classify neurotoxicity risk appropriately.

If TSB is at or above phototherapy level of appropriate neurotoxicity risk, repeat TSB within 4-6 hours if improvement is expected, or arrange for direct admission of the patient to the hospital. Order DAT from cord blood to classify neurotoxicity risk appropriately.

**Admission triage.** The best predictors of admission are elevated bilirubin (TcB or TSB) at 24-48 hours of life and gestational age. [1-C]37

If the bilirubin is at or above the level where intensive phototherapy is recommended [1-C]4 or if rate of rise is > 0.2 mg/dL/hour with a current bilirubin predicted to cross the treatment threshold prior to the next monitoring evaluation, a neonate should be admitted. [1-D]

Consideration for evaluation in Children’s Emergency Services should be given when there is concern for hemodynamic instability, sepsis, or other conditions in the neonate that would require immediate evaluation and resuscitation. For admission at UMHS, when a provider (PCP/newborn service/on-call nurse/other) has determined that a neonate requires hospitalization for management of hyperbilirubinemia, contact the hospitalist on-call (2288) for UMHS providers, and on-call admitting officer of the day for Mott hospital (AOD-Mott via transfer operator) for external (non-UMHS) PCPs to arrange for an admission.

In times of high occupancy, when phototherapy will be delayed > 4 hours, the hospitalist on-call or AOD will discuss admission to the NICU for care or consider referring patients who require admission for phototherapy to CES to initiate care. This excludes neonates within 2 mg/dL of exchange transfusion level as they should be admitted directly to the NICU.
Treatment

A primary goal of phototherapy is to prevent the need for exchange transfusion, a therapy that can acutely lower serum bilirubin values but also engenders risk. Phototherapy can also reduce serum bilirubin values but requires time for its therapeutic effect to become apparent. Because of this, risk-averse clinicians are obligated to “over treat” with phototherapy targeting neonates who are at risk for extreme hyperbilirubinemia. Once a neonate has crossed the risk threshold, treatment with a standardized approach to phototherapy is of value.

Home phototherapy. If a baby does not have neurotoxicity risk factors, is feeding well, and close follow up is arranged, and when the total bilirubin is 0-2 mg/dL below the treatment level, it is an option to discharge a baby from the birth hospitalization with home phototherapy. [II-D] Home phototherapy should not be used for babies with neurotoxicity risk factors (Table 1), nor those who have required intensive phototherapy. [III-D]

Although efficacy is not well documented, home phototherapy (ie, fiberoptic phototherapy blanket) may be considered in a well-appearing low risk neonate with a bilirubin that is 0-2 mg/dL below the phototherapy level. It may be considered in neonates who are medium risk due to gestational age but who are otherwise acting well. [III-C]

Neurotoxicity. Home phototherapy should not be used in neonates with neurotoxicity risk factors (Table 1). [III-C]

Inpatient phototherapy. Neonates at risk for developing significant hyperbilirubinemia should receive phototherapy. Phototherapy is in general effective at decreasing serum bilirubin values (TSB) and preventing the need for exchange transfusion. For the majority of term neonates, phototherapy using a single light source capable of emitting enough energy (irradiance) (30 microwatts/cm2/nm), in the spectrum of 460-490nm will be sufficient. Double light source phototherapy (overhead and fiberoptic blanket) may be indicated when the serum bilirubin values is rising rapidly (more than 0.5 mg/dl per hour), the serum bilirubin is at a level within 3 mg/dL below the threshold for which exchange transfusion is indicated or the bilirubin level fails to respond to initial phototherapy. Use of two angled overhead LED phototherapy lights in combination with a fiberoptic phototherapy blanket and white sheets as a reflective surface may be indicated when the serum bilirubin value is at or above the exchange transfusion threshold. This should be done in the NICU. Irradiance should be measured regularly. Fiberoptic phototherapy alone should not be used for intensive phototherapy.

Where there is hemolysis due to ABO incompatibility (positive DAT), efficacy is less certain. A risk-averse approach would be prudent. With a rapid rate of rise (0.2 mg/dL/hr) of bilirubin values and suspected hemolysis due to blood group incompatibility, consider phototherapy while waiting for confirmation of antibody-mediated hemolysis.

When neonates are not considered high risk for exchange transfusion (≥ 2 mg/dL below exchange level and < 0.2 mg/dL/hr rate of rise), phototherapy can be temporarily halted to allow for bonding and breast feeding.

Consider phototherapy in mother’s arms for neonates with severe hyperbilirubinemia, or for mothers who prefer to keep the neonate in skin-to-skin contact. The mother needs to wear eye protection (sunglasses).

When serum bilirubin values are at or near exchange transfusion values, take steps to insure “maximum” efficacy. Such steps may include:

- maximizing surface area by removing unnecessary clothing (i.e., minimal/no diaper)
- using multiple light sources (measure irradiance at various sites)
- using highly reflective materials (i.e; white sheets) surrounding a neonate to increase surface area exposed and irradiance
- consider adjunctive therapies including IVIG and IV “hydration” (see IVIG section, below).

Note: turning baby from prone to supine in an alternating fashion has not been shown to be efficacious.

Risk and risk mitigation. Though there is a paucity of evidence phototherapy has risk, melanocytic nevus development is a worry. Blue light can induce retinal photoreceptor degeneration in rats and in mammals. For most neonates a single overhead light will suffice.

- do not routinely exceed recommendations for maximal irradiance.
- stop phototherapy when indicated.
- eye masks to prevent damage to the retina are a simple and prudent prophylactic measure.

IV fluids. For most neonates with hyperbilirubinemia, IV supplementation is not warranted. It is recommended that dehydration in neonates with hyperbilirubinemia be treated similarly to any hospitalized neonate with dehydration.

For neonates with severe hyperbilirubinemia, IV fluid administration is recommended.

Dehydration can theoretically impede bilirubin excretion in urine by decreasing gut motility and increasing enterohepatic recirculation of bilirubin. There are at least 3 randomized controlled trials comparing IV fluid supplementation with no supplementation. Mehta at al found supplementing with IV fluids for the first 8 hours of phototherapy followed by enteral supplementation was associated with fewer exchange transfusions. Iranpour and colleagues conducted a similar study in which “dehydrated” neonates were excluded. No meaningful differences in outcome were found. Saeidi et al performed a randomized, controlled trial in 100 well appearing neonates and found the mean decrease in TCB at 24 hours of phototherapy was greater with IV supplementation. Boo et al reviewed fluid supplementation provided either entirely enteral or as a combination of enteral and IV fluids. No differences in indirect serum bilirubin were
appreciated, suggesting either oral/enteral supplementation is as beneficial as IV (or there is no efficacy to either).

**IVIG.** Use of IVIG may be useful in Rh or ABO disease. Use should be restricted to select neonates in the NICU with high bilirubin values or rapid rate of rise (at high risk for exchange transfusion). Neonates should be monitored closely. Dose 0.5 g/kg over 2 hours, and repeat as clinically indicated.

During the trial of intensive phototherapy, patients with Rh or ABO mediated hemolysis should receive IVIG (0.5 – 1.0 g/kg over 4 hours).

**Exchange Transfusion.** In the absence of high quality evidence for the efficacy of exchange transfusions, we rely on guidelines promulgated by the AAP and National Institute for Health and Clinical Excellence. An exchange transfusion should be considered when a serum bilirubin value surpasses the applicable AAP recommended threshold value (Figures 4 & 5).

A decision to delay or forgo the transfusion will depend upon the subsequent TSB value, the rate of fall of TSB, and the perceived underlying vulnerability of the neonate. Failure of the TSB value to fall necessitates exchange transfusion.

For the neonate who presents as an outpatient or in whom a trial of phototherapy has not been done, a trial of intense phototherapy is indicated. Exceptions include the neonate who exhibits signs of ABE (including opisthotonos and retrocollis), or in whom intense phototherapy is not likely to be of benefit. The latter includes a neonate who present with TSB values so high that it is unlikely that a period of phototherapy will lower TSB to < 25 mg/dL, or in whom the rate of rise is predicted to be faster than the expected fall associated with phototherapy.

Consider using albumin prior to transfusion (see below).

The exchange transfusion should be a double-volume exchange transfusion and done in the NICU under the direct supervision of a neonatologist. (At UMHS, technical guidelines can be found in the Brandon NICU.)

Continue phototherapy during the exchange transfusion.

Monitor for potential adverse sequelae including leukopenia, thrombocytopenia, hypocalcemia, hypernatremia, and bacteremia. A post-exchange blood sample looking for chemical abnormalities is recommended (CBC, PLT, Ca, Na [and TSB]). Calcium need not be administered in the absence of bradycardia.

**Albumin.** There is a paucity of evidence surrounding the use of albumin as adjunctive therapy in neonates requiring exchange transfusion and it is used only in the NICU. A single RCT showed the use of albumin priming prior to exchange transfusion (1 mg/kg, 1 hour before exchange transfusion) resulted in lower TBS values at 12 hours and a shorter length of stay for neonates receiving albumin. If used, fluid status and effects of overhydrating should be monitored.

### Monitoring

**Home phototherapy.** If a patient is being treated with home phototherapy, check total serum bilirubin every 24 hours in a medium risk neonate with no neurotoxicity risk factors.\(^4,22\) In a low risk neonate 38 weeks gestation or greater, total serum bilirubin may be checked every 24-48 hours. \(^4,22\)

**Inpatient phototherapy.** Total bilirubin should be followed using serum, not transcutaneous, levels while on phototherapy and after discontinuing phototherapy. \(^4,22\) Transcutaneous bilirubin levels are significantly lower compared with serum levels once phototherapy has been initiated.\(^4,44,45\) Phototherapy is expected to decrease total bilirubin levels by 30-40% in the first 24 hours, with most of the decrease in the first 4-6 hours.\(^4\)

**Discontinuation of intensive phototherapy.** When a neonate is readmitted for hyperbilirubinemia, phototherapy should be stopped when the level is less that 13-14 mg/dL. \(^4,44\) If lowered to < 14, there is a significantly decreased risk of requiring repeat phototherapy.\(^4,47\) In the absence of hemolysis, a higher level may be used for discontinuation, such as a level 3 mg/dL below current treatment level. \(^4,46,48\) Discontinuation at a lower level may be appropriate during the birth hospitalization since treatment levels are lower in the first days of life. \(^4,49\)

**Rebound.** Hospital discharge should not be delayed to obtain a rebound level. \(^4,49,47\) Rebound bilirubin levels 6 hours after discontinuing phototherapy are not predictive of subsequent repeat phototherapy.\(^4,46\) A repeat bilirubin level 24 hours after discontinuing phototherapy should be considered in babies for whom phototherapy was required during the birth hospitalization,\(^4,22\) and for babies with a positive DAT or gestational age < 37 weeks. \(^4,49\)

### Follow-up

Schedule outpatient evaluation by provider within 1-3 (see above, outpatient assessment) days following birth hospitalization discharge to evaluate neonates weight, percent change from the birth weight, adequacy of feeding, pattern of voiding and stooling, and presence of jaundice. Close follow up is recommended after initial evaluation after discharge to ensure adequate feeding in exclusively breastfed neonates.

If ongoing feeding difficulties, dehydration, or other concerns are present at outpatient evaluations, order total serum bilirubin level for evaluation.

**Management of TSB results:**
- TSB is less than discharge level, no further measurement is needed
Related National Guidelines

The UMHS Clinical Guideline on Management of Indirect Neonatal Hyperbilirubinemia is generally consistent with the following national and international guidelines:


Related National Performance Measures

There are no national performance measures associated with hyperbilirubinemia.

Guideline Development Methodology

Funding

The development of this guideline was funded by the University of Michigan Health System.

Guideline Development Team and Disclosures

The multidisciplinary guideline development team consisted of:

- Primary care physicians: Sahoko H Little, MD; Maria S Skoczylas, MD
- Specialists: Jennifer L Vredeveld, MD; Michael Levy, MD; Robert E Schumacher, MD; Nicole S Sroufe, MD
- Nursing: Linda D Gobeski, RN; Debra K Horvath, RN; Pamela K Hurley, RN; Kelly A McCarley, RN; Michelle Nemshak MSN, RNC-NIC, CNS; Carolyn M Pawlowski, RN; Rebecca Pehovic, MS, RN, CNS-BC; Deborah R Retzer, RN; Kristin Schuster, RN
- A guideline development methodologist: F. Jacob Seagull, PhD, Learning Health Sciences.
- Literature search services were provided by informationists at the Taubman Health Sciences Library, University of Michigan Medical School.

The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.

No relevant personal financial relationships with commercial entities: Linda D Gobeski, RN; Debra K Horvath, RN; Pamela K Hurley, RN; Michael Levy, MD; Sahoko H Little, MD; Kelly A McCarley, RN; Michelle Nemshak MSN, RNC-NIC, CNS; Carolyn M Pawlowski, RN; Rebecca Pehovic, MS, RN, CNS-BC; Deborah R Retzer, RN; Kristin Schuster, RN; F Jacob Seagull, PhD; Maria S Skoczylas, MD; Nicole S. Sroufe, MD, MPH; Jennifer L Vredeveld, MD

Relevant personal financial relationships with commercial entities: None.

Strategy for Literature Search

Within the Medline (Ovid) database, the following search strategy was used.

1. exp *hyperbilirubinemia, neonatal/
2. *hyperbilirubinemia/ or jaundice/ or kernicterus/
3. limit 2 to "all infant (birth to 23 months)"
4. (neonatal or neonate* or infant* or newborn*).ti.
5. 2 and 4
6. exp animals/ not (exp animals/ and humans/)
7. 5 not 6
8. 1 or 3 or 7
9. limit 8 to (english language and yr="2004 -Current")

The search was not focused on indirect hyperbilirubinemia because the retrieval was very small. The Main search retrieved 1,213 references. When the search hedges for Guidelines, Clinical Trials, and Cohort Studies were added, the base results are as follow:

- Neonatal Hyperbilirubinemia -Guidelines, total results were 35
- Neonatal Hyperbilirubinemia -Clinical Trials, total results were 125
- Neonatal Hyperbilirubinemia -Cohort Studies, total results were 262

The MEDLINE In-Process database was also searched using the strategy in the search strategies document. The search
retrieved 100 documents. The results with the hedges applied are:
Guidelines, total results were 2
Clinical Trials, total results were 11
Cohort Studies, total results were 21

Within the Cochrane Database of Systematic Reviews, 6 reviews were found using the strategy in the search strategies document.

The search was conducted in components each keyed to a specific causal link in a formal problem structure (available upon request). The search was supplemented with very recent clinical trials known to expert members of the panel. Negative trials were specifically sought. The search was a single cycle.

Level of evidence supporting a diagnostic method or an intervention:
A= systematic reviews of randomized controlled trials
B= randomized controlled trials
C=systematic review of non-randomized controlled trials or observational studies, non-randomized controlled trials, group observation studies (e.g., cohort, cross-sectional, case control)
D= individual observation studies (case or case series)
E =opinion of expert panel.


**Recommendations**

Guideline recommendations were based on prospective randomized controlled trials if available, to the exclusion of other data; if RCTs were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size. The “strength of recommendation” for key aspects of care was determined by expert opinion.

The strength of recommendations regarding care were categorized as:
I = Generally should be performed
II = May be reasonable to perform
III = Generally should not be performed

**Review and Endorsement**

Drafts of this guideline were reviewed in clinical conferences and by distribution for comment within departments and divisions of the University of Michigan Health System to which the content is most relevant: Family Medicine, Pediatrics, Pediatric Emergency Medicine, Pediatric Internal Medicine. The Executive Committee for Clinical Affairs of the University of Michigan Hospitals and Health Centers endorsed the final version.

**References**


13. World Health Organization. Guidelines on maternal, newborn, child and adolescent health approved by the


in infants at more than 37 weeks' gestation. *Cochrane Database of Systematic Reviews*. 2014;6:010212.


Appendix 1. Bhutani Nomogram


Reproduced with permission from American Academy of Pediatrics Journal, Vol. 103, Page 9, copyright 1999 by AAP

Appendix 2. Internal UMHS Guidelines

Transfer of newborn from well newborn to the floor: [http://www.med.umich.edu/i/nursing-birthcenter/docs/ptPlacement.pdf](http://www.med.umich.edu/i/nursing-birthcenter/docs/ptPlacement.pdf)

TcB measurement in the newborn nursery: [http://cw.i.medicine.umich.edu/sites/default/files/policies/trans_bili.pdf](http://cw.i.medicine.umich.edu/sites/default/files/policies/trans_bili.pdf)


After hours phlebotomy: [http://www.med.umich.edu/i/em/Clinical_Guidelines/Phlebotomy_After_Hours.pdf](http://www.med.umich.edu/i/em/Clinical_Guidelines/Phlebotomy_After_Hours.pdf); [http://inted.sites.uofmhosting.net/sites/default/files/downloads/Phlebotomy_After_Hours.pdf](http://inted.sites.uofmhosting.net/sites/default/files/downloads/Phlebotomy_After_Hours.pdf)

Appendix 3. Bilitool.info

“Bilitool” ([http://bilitool.info](http://bilitool.info)) is a resource that can be used to help providers calculate treatment thresholds for hyperbilirubinemia. This tool should not be used alone to drive medical decision making. This site allows a provider to input the age (in hours) and total bilirubin level. The “Recommended Follow Up” table looks at risk for development of severe hyperbilirubinemia. This should not be confused with neurotoxicity risk factors used to determine treatment thresholds. The recommended follow up ranges are often quite broad. The “AAP Phototherapy Guidelines” table will give the treatment threshold based on the AAP nomograms for each neurotoxicity risk level. For convenience, these values can be used rather than manually plotting data on the AAP nomograms.